Articles which will keep customers informed of any updates and changes to the system that they need to be aware of.
We’re moving all of our drug data into one place. The ‘One Drug Database’ project is underway to provide a consistent, single source of information. The first release of new data is due in January 2020 (for November 2019 data).
There will be differences in the way data is presented.
You can read more about the project, and how this affects our systems and reports.
Diabetes Dashboard update
The following metrics have changed:
- Metric 1: Number of unique patients prescribed Blood Glucose Testing Strips with any non-insulin blood glucose lowering therapies and not prescribed insulin.
- Metric 2: Number of unique patients prescribed Blood Glucose Testing Strips with Metformin but no insulin.
- Metric 3: Number of unique patients prescribed Blood Glucose Testing Strips with any non-insulin blood glucose-lowering therapy and insulin.
Previously, the metrics included patients who were not prescribed blood glucose testing strips, as well as those who were.
This has been changed to include only patients who were prescribed testing strips, and match the rest of the prescribing combination for the metrics:
- Metric 1: Number of unique patients prescribed Blood Glucose Testing Strips and any non-insulin blood glucose-lowering therapies and not prescribed insulin.
- Metric 2: Number of unique patients prescribed Blood Glucose Testing Strips and Metformin but no insulin.
- Metric 3: Number of unique patients prescribed Blood Glucose Testing Strips and any non-insulin blood glucose-lowering therapy AND insulin.
This will have an impact on figures, removing approximately 85% of patients from metrics 1 and 2, and 25% of patients from metric 3 nationally.
The change has been made because the focus of the metrics is on the use of testing strips. It's important to make sure that only patients prescribed the testing strips are included.
This change will affect all three graphics for these metrics, for all organisation levels.
One Drug Database
For many years we had 2 sources of drug data. These were Master Data Replacement (MDR) and Common Drug Reference (CDR).
The MDR database is used for reporting purposes whilst the CDR database is used for the transactional processing of prescription items.
There are inconsistencies in how the data is stored in each of the databases which can cause confusion, especially as different naming conventions are used in both systems.
We are running a project to improve this situation by migrating all drug usage to CDR and decommissioning the MDR Drug system completely.
Moving to one source of drug information will save the effort of maintaining 2 sets of drug records and improve quality by making sure all of our applications, and external customers of drug data, are using a single and consistent source of drug data.
Delivering these benefits directly contributes to our strategic goals, which are to generate efficiency across health and social care system, make things easy for our customers through the delivery of brilliant basics, and to collaborate to maximise the return on data to improve health outcomes for patients.
The project is underway and will hopefully be completed by the end of this calendar year, where all drug data which is currently held only in MDR will be migrated to CDR which will be then be the one single data source.
We'll continue to keep you updated with our progress on this
ePACT2 newsletter is produced monthly to inform customers of updates and changes to the system.Issue 19 (PDF: 346KB)Issue 18 (PDF: 325KB)Issue 17 (PDF: 339KB)Issue 16 (PDF: 455KB)Issue 15 (PDF: 581KB)Issue 14 (PDF: 567KBIssue 13 (PDF: 310KB)Issue 12 (PDF: 454KB)Issue 11 (PDF: 614KB)Issue 10 (PDF: 628KB)Issue 9 (PDF: 608KB)Special Edition - November 2018 ePACT2 migration complete (PDF:604KB)Issue 8 (PDF: 646KB)Special Edition - November 2018 (PDF: 572KB)Issue 7 (PDF: 334KB)Issue 6 (PDF: 600KB)Issue 5 (PDF: 578KB)Issue 4 (PDF: 578KB)Issue 3 (PDF: 610KB)Issue 2 (PDF: 539KB)Issue 1 (PDF: 560KB)